Immunogenicity and safety of 'Comvigen', a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial.
Jantarabenjakul W, Nantanee R, Puthanakit T, Gatechompol S, Avihingsanon A, Punrin S, Tantawichien T, Nitayaphan S, Thitithanyanont A, Buranapraditkun S, Jongkaewwattana A, Ketloy C, Prompetchara E, Lawpoolsri S, Wijagkanalan W, Alameh MG, Hong L, Samija M, Weissman D, Ruxrungtham K; ChulaVac006 Study Team.
Jantarabenjakul W, et al.
Lancet Reg Health Southeast Asia. 2025 Aug 15;40:100650. doi: 10.1016/j.lansea.2025.100650. eCollection 2025 Sep.
Lancet Reg Health Southeast Asia. 2025.
PMID: 40895389
Free PMC article.